Moleculin Biotech, Inc. — Form 8-K summary
Reporting context: The 8-K reports an amendment to the company’s certificate of incorporation implementing a reverse stock split. The report date and press release are October 16, 2026; the filing was signed October 20, 2026. Stockholders approved authority for a split at the October 9 annual meeting.
Reverse stock split
- The board selected a 1-for-20 reverse split, effective at 12:01 a.m. Eastern Time on October 20, 2026. The common stock is to trade on Nasdaq Capital Market on a post-split basis under ticker MBRX, with a new CUSIP number.
- Every 20 outstanding shares will combine into one share. Outstanding common shares are expected to fall from approximately 20.91 million to approximately 1.05 million. Authorized common shares remain 500 million; par value remains $0.001 per share.
- Options, restricted stock units, warrants, and equity-plan share reserves will be adjusted proportionately. Option and warrant exercise prices will increase proportionately. Fractional shares will be paid in cash based on the average closing price over the five trading days before the split.
Financial information and changes
The filing provides no current revenue, cash flow, margin, debt, or liquidity figures, and no financial guidance. It includes retrospective per-share and weighted-average-share data; the split changes those share-based measures but does not change reported net loss.
| Period | Net loss | Post-split loss per share | Post-split weighted-average shares |
|---|---|---|---|
| Year ended Dec. 31, 2025 | $33.560 million | $568.38 | 59,228 |
| Year ended Dec. 31, 2024 | $26.048 million | $3,782.75 | 6,886 |
| Six months ended June 30, 2026 | $20.480 million | $92.01 | 245,345 |
| Six months ended June 30, 2025 | $23.713 million | $952.18 | 24,904 |
The filing notes that 2024 net loss was retrospectively adjusted from $21.763 million to $26.048 million following a change in accounting policy in September 2025. The split-adjusted figures are historical presentations, not forecasts.
Outlook, risks, and items to verify
The filing gives no operating outlook or management commentary on business performance. It does not describe contingencies beyond the split’s fractional-share cash treatment.
- Verify the split’s effective date and post-split trading and settlement details with the company or broker.
- Confirm account-level share, option, warrant, and equity-award adjustments, including any cash paid for fractional shares.
- Review the full certificate amendment and subsequent filings for any additional corporate actions or updated share counts.
- Do not interpret the higher post-split loss-per-share figures as a change in the underlying net loss; the filing presents them on a 1-for-20 adjusted basis.